Disease-modifying treatments in Alzheimer’s disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Disease-modifying treatments in Alzheimer’s disease ; volume:270 ; number:4 ; day:16 ; month:2 ; year:2023 ; pages:2342-2344 ; date:4.2023
Journal of neurology ; 270, Heft 4 (16.2.2023), 2342-2344, 4.2023

Creator: Edwards, Marc
Corkill, Robin

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00415-023-11602-8

URN: urn:nbn:de:101:1-2023080721092848919334

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:02 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Edwards, Marc
Corkill, Robin
SpringerLink (Online service)

Other Objects (12)

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Treatments in Alzheimer’s disease

New treatments in Alzheimer’s disease

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Treatments in Alzheimer’s disease

New treatments in Alzheimer’s disease

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Treatments in Alzheimer’s disease

New treatments in Alzheimer’s disease

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Disease-modifying treatments in Alzheimer’s disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Treatments in Alzheimer’s disease

New treatments in Alzheimer’s disease

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Treatments in Alzheimer’s disease

New treatments in Alzheimer’s disease

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Treatments in Alzheimer’s disease

New treatments in Alzheimer’s disease

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

Related objects

Reset password